The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis
A study to observe hospitalized infants with respiratory syncytial virus (RSV)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAO6713
U.S. Govt. ID: NCT02273882
Contact: Hossein Sadeghi: 212-305-5122 / hs762@columbia.edu
Additional Study Information: The purpose of this research study is to gather information about how respiratory syncytial virus (RSV) disease affects babies who were born earlier than their full-term due date, and how the hospitalization for RSV disease affects the parents/guardians daily routine activities. Information about the cost of healthcare and other costs related to the RSV disease will also be collected.
This study is closed
Investigator
Hossein Sadeghi, MD
Do You Qualify?
Does your infant have a confirmed diagnosis of RSV? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Hossein Sadeghi
hs762@columbia.edu
212-305-5122
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE